Abstract
BackgroundIn preclinical studies, administration of antibodies that neutralize sclerostin results in increased bone mass and strength.ObjectivesWe report the primary and key secondary endpoints of a phase 2 trial evaluating the...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
